Loading
MMP7 (Matrilysin) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.99, animal model 0.26, genetic association 0.61, clinical 0.65).
In plain words · MMP7 (Matrilysin) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
MMP7 (Matrilysin) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase.
No product in this corpus aims at MMP7 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MMP7: RNA tissue enhanced (gallbladder 479 nTPM, salivary gland 253 nTPM, urinary bladder 197 nTPM); no normal tissue stained high; highest cancer staining endometrial cancer (2 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (prostate carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MMP7 tissue; Open Targets ENSG00000137673 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Muller et al, Biochem. J, 1988, "The collagenase gene family in humans consists of at least four members". Source.
Sources: HGNC HGNC:7174 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09237 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000137673 (association with cancer (MONDO_0004992) 0.57; (GraphQL API, CC0))
Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 11q22.2 (HGNC).
RNA: tissue enhanced (gallbladder 479 nTPM, salivary gland 253 nTPM, urinary bladder 197 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Gallbladder, Kidney.
RNA cancer enhanced: Pancreatic Adenocarcinoma 1,153 pTPM, Uterine Corpus Endometrial Carcinoma 957 pTPM.
Medium only: cervical cancer, colorectal cancer, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MMP7" OR ABSTRACT:"MMP7" OR TITLE:"matrix metallopeptidase 7" OR ABSTRACT:"matrix metallopeptidase 7" OR TITLE:"Matrilysin" OR ABSTRACT:"Matrilysin" OR TITLE:"PUMP-1" OR ABSTRACT:"PUMP-1" OR TITLE:"MPSL1" OR ABSTRACT:"MPSL1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MMP7, not a curated reading list.